vTv Therapeutics

VTVT · NASDAQ

$27.85+$0.905 (+3.36%)TodayMarket closed ·
Prev close $26.94

Latest news

  • News

    vTv Therapeutics Q1 EPS $1.65 Beats $(0.10) Estimate, Sales $36.839M Beat $20.000M Estimate

  • Press releaseGlobe Newswire

    vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

  • Press releaseGlobe Newswire

    vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

  • NewsAvi Kapoor

    This vTv Therapeutics Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

  • News

    vTv Therapeutics And M42's IROS Submits Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health; This Study Constitutes The Longest Trial Investigating Cadisegliatin To Date

  • Press releaseGlobe Newswire

    vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseGlobe Newswire

    vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

  • NewsAvi Kapoor

    Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket

  • Press releaseGlobe Newswire

    vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

  • Press releaseGlobe Newswire

    vTv Therapeutics to Participate in the H.C. Wainwright "HCW@Home" Series

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • News

    12 Health Care Stocks Moving In Monday's Intraday Session

  • News

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releasePRNewswire

    CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

  • Press releaseGlobe Newswire

    vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

  • NewsAvi Kapoor

    Dow Edges Lower; Ventyx Biosciences Shares Plummet

  • NewsAvi Kapoor

    Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session

  • NewsAvi Kapoor

    Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump

  • NewsAvi Kapoor

    Nasdaq Gains 1%; McDonald's Posts Downbeat Results

  • NewsAvi Kapoor

    Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.